BioView Reports Encouraging Interim Results of Lung Cancer Diagnostic Test
Posted on: Friday, 26 September 2008, 09:00 CDT
Israel-based laboratory equipment developer BioView has reported positive results of its internal clinical trial of the non-invasive diagnostic test under development for early detection of lung cancer.
In the trial, a total of 76 sputum samples were collected from four groups of patients, healthy individuals that never smoked, heavy smokers with no signs of lung cancer, early stage lung cancer patients (stage 1) and advanced stage lung cancer patients.
The sputum samples were blindly scanned and analyzed morphologically and genetically, with fluorescent probes exclusively licensed to BioView, on BioView's automated Duet scanning station by company personnel.
The results of the test were classified as 'normal'(no cancer detected) and 'abnormal'(cancer detected). These results were then compared to the actual data received from the hospital of the patients' condition.
The samples included 32 cases of lung cancer patients and 44 samples taken from people with no clinical evidence of lung cancer. Approximately 31 of 32 (96.9%) sick patients were correctly diagnosed as 'abnormal' and 36 of 44 (about 82%) healthy people were correctly diagnosed as 'normal'.
Opher Shapira, CEO of BioView, said: "We are extremely pleased with the results; the specificity and sensitivity in this test are better than other non-invasive tests presently available for early lung cancer detection. We are accelerating our development efforts to improve these results as well as to increase our sample size and to include other laboratories in the clinical trials."
Source: Datamonitor
Related Articles
- PhytoMedical's In Vivo Toxicity and Efficacy Tests on Human Colon Cancer Deliver Promising Results
- Randomized Phase 2 Study of IMC-A12 and IMC-1121B for Advanced Prostate Cancer Commences Patient Enrollment
- Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated With AERx(R) Insulin Diabetes Management System (iDMS)
- Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal Women
- Preliminary Results From VioQuest Pharmaceuticals' Phase I Trial of Novel Akt Inhibitor VQD-002 in Patients With Advanced Leukemias Demonstrate Promising Clinical Activity
- SciClone Acquires Clinical-Stage Pancreatic Cancer Compound
- Somaxon's SILENOR(TM) Demonstrates Positive Results in Long-Term Phase 3 Clinical Trial in Elderly Patients With Insomnia
- Locus Pharmaceuticals Submits IND on Cancer Drug Candidate; First IND Establishes Transition to Clinical Stage Company
- Top German Cancer Center Delivers Advanced Gated Radiation Treatments for Lung Patients
- HMGI(Y) Gene Expression in Colorectal Cancer: Comparison with some Histological Typing, Grading, and Clinical Staging
 |
 |
User Comments (0)
RSS Feeds